Skip to main content
Erschienen in: European Radiology 9/2020

25.04.2020 | Hepatobiliary-Pancreas

Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid–enhanced MRI in transplantation candidates

verfasst von: Sun Kyung Jeon, Jeong Min Lee, Ijin Joo, Jeongin Yoo, Jin-young Park

Erschienen in: European Radiology | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To compare diagnostic performances of current guidelines for the diagnosis of HCC in LT candidates using gadoxetic acid–enhanced liver MRI (Gd-EOB-MRI).

Methods

Eighty-one patients (119 HCCs and 35 non-HCCs) who underwent preoperative Gd-EOB-MRI and subsequent LT were included. Per-lesion imaging diagnoses of HCCs were made using four different guidelines (American Association for the Study of Liver Disease (AASLD), European Association for the Study of the Liver (EASL), Asian Pacific Association for the Study of the Liver (APASL), and Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) guidelines, and patient allocation was determined according to Milan criteria (MC). Comparisons of per-lesion sensitivity, specificity, and accuracy of patient allocation between guidelines were performed using logistic regression with generalized estimating equations.

Results

For diagnosis of HCC, AASLD guideline showed highest specificity (97.4%), followed by EASL and KLCA-NCC guidelines (92.1% and 92.1%, p > 0.99 and = 0.15, respectively, in comparison to AASLD), while the specificity of APASL guideline was significantly lower than that of AASLD guideline (78.9% vs. 97.4%, p = 0.006). APASL and KLCA-NCC guidelines (75.9% and 65.6%) showed significantly higher sensitivities than AASLD/EASL guidelines (34.5% and 38.8%, respectively; all ps < 0.001). For organ allocation, KLCA-NCC guideline showed higher accuracy in selecting unsuitable candidates (with non-HCC malignancies or beyond MC HCCs) than EASL guideline (68.4% vs. 31.8%; p = 0.001).

Conclusion

For the diagnosis of HCCs using Gd-EOB-MRI, AASLD guideline provided the highest specificity, followed by EASL, KLCA-NCC, and APASL guidelines with statistically significant difference with only APASL guideline. KLCA-NCC guideline provided the most accurate selection of unsuitable LT candidates.

Key Points

AASLD/LI-RADS showed the highest specificity, followed by EASL and KLCA-NCC guidelines.
APASL and KLCA-NCC guidelines allowed more sensitive diagnoses of HCCs.
KLCA-NCC more accurately classified patients not appropriate transplantation candidates than EASL.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Villanueva A (2019) Hepatocellular carcinoma. N Engl J Med 380:1450–1462CrossRef Villanueva A (2019) Hepatocellular carcinoma. N Engl J Med 380:1450–1462CrossRef
2.
Zurück zum Zitat Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A (2012) Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 13:e11–e22CrossRef Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A (2012) Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 13:e11–e22CrossRef
3.
Zurück zum Zitat Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J (2013) New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 266:376–382CrossRef Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J (2013) New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 266:376–382CrossRef
4.
Zurück zum Zitat Fowler KJ, Sirlin CB (2019) Is it time to expand the definition of washout appearance in LI-RADS? Radiology 291:658–659CrossRef Fowler KJ, Sirlin CB (2019) Is it time to expand the definition of washout appearance in LI-RADS? Radiology 291:658–659CrossRef
5.
Zurück zum Zitat Kim TH, Kim SY, Tang A, Lee JM (2019) Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 25:245–263CrossRef Kim TH, Kim SY, Tang A, Lee JM (2019) Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 25:245–263CrossRef
6.
Zurück zum Zitat Omata M, Cheng AL, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317–370CrossRef Omata M, Cheng AL, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317–370CrossRef
7.
Zurück zum Zitat Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750CrossRef Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750CrossRef
8.
Zurück zum Zitat Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380CrossRef Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380CrossRef
9.
Zurück zum Zitat European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69:182–236 European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69:182–236
10.
Zurück zum Zitat Korean Liver Cancer Association; National Cancer Center (2019) 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 13:227–299 Korean Liver Cancer Association; National Cancer Center (2019) 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 13:227–299
11.
Zurück zum Zitat Kim TH, Yoon JH, Lee JM (2019) Emerging role of Hepatobiliary magnetic resonance contrast media and contrast-enhanced ultrasound for noninvasive diagnosis of hepatocellular carcinoma: emphasis on recent updates in major guidelines. Korean J Radiol 20:863–879CrossRef Kim TH, Yoon JH, Lee JM (2019) Emerging role of Hepatobiliary magnetic resonance contrast media and contrast-enhanced ultrasound for noninvasive diagnosis of hepatocellular carcinoma: emphasis on recent updates in major guidelines. Korean J Radiol 20:863–879CrossRef
12.
Zurück zum Zitat Lee YJ, Lee JM, Lee JS et al (2015) Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 275:97–109CrossRef Lee YJ, Lee JM, Lee JS et al (2015) Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 275:97–109CrossRef
13.
Zurück zum Zitat Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7:462–503CrossRef Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7:462–503CrossRef
14.
Zurück zum Zitat Chernyak V, Fowler KJ, Kamaya A et al (2018) Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 289:816–830CrossRef Chernyak V, Fowler KJ, Kamaya A et al (2018) Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 289:816–830CrossRef
15.
Zurück zum Zitat Ren AH, Zhao PF, Yang DW, Du JB, Wang ZC, Yang ZH (2019) Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017. J Magn Reson Imaging 50:746–755CrossRef Ren AH, Zhao PF, Yang DW, Du JB, Wang ZC, Yang ZH (2019) Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017. J Magn Reson Imaging 50:746–755CrossRef
16.
Zurück zum Zitat Lee SM, Lee JM, Ahn SJ, Kang HJ, Yang HK, Yoon JH (2019) LI-RADS version 2017 versus version 2018: diagnosis of hepatocellular carcinoma on gadoxetate disodium-enhanced MRI. Radiology 292:655–663CrossRef Lee SM, Lee JM, Ahn SJ, Kang HJ, Yang HK, Yoon JH (2019) LI-RADS version 2017 versus version 2018: diagnosis of hepatocellular carcinoma on gadoxetate disodium-enhanced MRI. Radiology 292:655–663CrossRef
17.
Zurück zum Zitat Fraum TJ, Tsai R, Rohe E et al (2018) Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk: diagnostic performance of the liver imaging reporting and data system version 2014. Radiology 286:158–172CrossRef Fraum TJ, Tsai R, Rohe E et al (2018) Differentiation of hepatocellular carcinoma from other hepatic malignancies in patients at risk: diagnostic performance of the liver imaging reporting and data system version 2014. Radiology 286:158–172CrossRef
18.
Zurück zum Zitat Ludwig DR, Fraum TJ, Cannella R et al (2019) Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of liver imaging reporting and data system v2018. Abdom Radiol (NY) 44:2116–2132CrossRef Ludwig DR, Fraum TJ, Cannella R et al (2019) Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of liver imaging reporting and data system v2018. Abdom Radiol (NY) 44:2116–2132CrossRef
19.
Zurück zum Zitat Kulik L, Heimbach JK, Zaiem F et al (2018) Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology 67:381–400CrossRef Kulik L, Heimbach JK, Zaiem F et al (2018) Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology 67:381–400CrossRef
20.
Zurück zum Zitat Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY (2016) Intention to treat outcome of T1 hepatocellular carcinoma with the “wait and not ablate” approach until meeting T2 criteria for liver transplant listing. Liver Transpl 22:178–187CrossRef Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY (2016) Intention to treat outcome of T1 hepatocellular carcinoma with the “wait and not ablate” approach until meeting T2 criteria for liver transplant listing. Liver Transpl 22:178–187CrossRef
21.
Zurück zum Zitat Bruix J, Reig M, Sherman M (2016) Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150:835–853CrossRef Bruix J, Reig M, Sherman M (2016) Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150:835–853CrossRef
22.
Zurück zum Zitat Harper AM, Edwards E, Washburn WK, Heimbach J (2016) An early look at the organ procurement and transplantation network explant pathology form data. Liver Transpl 22:757–764CrossRef Harper AM, Edwards E, Washburn WK, Heimbach J (2016) An early look at the organ procurement and transplantation network explant pathology form data. Liver Transpl 22:757–764CrossRef
23.
Zurück zum Zitat Freeman RB, Mithoefer A, Ruthazer R et al (2006) Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl 12:1504–1511CrossRef Freeman RB, Mithoefer A, Ruthazer R et al (2006) Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl 12:1504–1511CrossRef
24.
Zurück zum Zitat Park JW, Chen M, Colombo M et al (2015) Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int 35:2155–2166CrossRef Park JW, Chen M, Colombo M et al (2015) Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int 35:2155–2166CrossRef
25.
Zurück zum Zitat Tang A, Cruite I, Mitchell DG, Sirlin CB (2018) Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ. Abdom Radiol (NY) 43:3–12CrossRef Tang A, Cruite I, Mitchell DG, Sirlin CB (2018) Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ. Abdom Radiol (NY) 43:3–12CrossRef
26.
Zurück zum Zitat Lee DH, Lee JM, Baek JH, Shin CI, Han JK, Choi BI (2015) Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings. Radiology 274:149–160CrossRef Lee DH, Lee JM, Baek JH, Shin CI, Han JK, Choi BI (2015) Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings. Radiology 274:149–160CrossRef
27.
Zurück zum Zitat Kim DH, Choi SH, Kim SY, Kim MJ, Lee SS, Byun JH (2019) Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: value of washout in transitional and hepatobiliary phases. Radiology 291:651–657CrossRef Kim DH, Choi SH, Kim SY, Kim MJ, Lee SS, Byun JH (2019) Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: value of washout in transitional and hepatobiliary phases. Radiology 291:651–657CrossRef
28.
Zurück zum Zitat Joo I, Lee JM, Lee DH, Jeon JH, Han JK (2019) Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? Eur Radiol 29:1724–1732CrossRef Joo I, Lee JM, Lee DH, Jeon JH, Han JK (2019) Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? Eur Radiol 29:1724–1732CrossRef
29.
Zurück zum Zitat Kierans AS, Makkar J, Guniganti P et al (2019) Validation of liver imaging reporting and data system 2017 (LI-RADS) criteria for imaging diagnosis of hepatocellular carcinoma. J Magn Reson Imaging 49:e205–e215CrossRef Kierans AS, Makkar J, Guniganti P et al (2019) Validation of liver imaging reporting and data system 2017 (LI-RADS) criteria for imaging diagnosis of hepatocellular carcinoma. J Magn Reson Imaging 49:e205–e215CrossRef
30.
Zurück zum Zitat Jeon SK, Joo I, Lee DH et al (2019) Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol 29:373–382CrossRef Jeon SK, Joo I, Lee DH et al (2019) Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol 29:373–382CrossRef
Metadaten
Titel
Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid–enhanced MRI in transplantation candidates
verfasst von
Sun Kyung Jeon
Jeong Min Lee
Ijin Joo
Jeongin Yoo
Jin-young Park
Publikationsdatum
25.04.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 9/2020
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-020-06881-y

Weitere Artikel der Ausgabe 9/2020

European Radiology 9/2020 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.